-

Feinstein Institutes’ Christina Brennan Named to Association of Clinical Research Professionals Board

MANHASSET, N.Y.--(BUSINESS WIRE)--Christina Brennan, MD, MBA, vice president of clinical research at Northwell Health’s Feinstein Institutes for Medical Research, has been elected by members of the Association of Clinical Research Professionals (ACRP) to serve on its Board of Trustees for a second term.

“Especially in these ever-changing times and focus on clinical research, it is an honor to be elected to the ACRP’s Board of Trustees once again,” said Dr. Brennan. “As a member, I support the mission of ACRP and I hope to contribute to the future success of the organization and future of clinical researchers.”

ACRP is a nonprofit organization based in Washington, D.C., that supports clinical research professionals and offers tools for its 13,000 members through eLearning to develop skills and improve operations. Beyond webinars and other clinical development programs for researchers – addressing regulatory developments, industry trends and best practices – the ACRP also serves as a career resource for job opportunities and maintains an online community to connect with peers. Dr. Brennan is the immediate past president of ACRP’s New York Metropolitan Chapter and is an active member of the Clinical Trial Transformation Initiative with Duke University and the U.S. Food and Drug Administration.

Throughout the coronavirus disease 2019 (COVID-19) pandemic, Dr. Brennan led the nearly 20 clinical trials and projects initiated across the health system, which enrolled more than 1,900 participants. From potential over-the-counter therapeutics to the study of industry-sponsored treatments and vaccine booster clinical trials, these COVID-19 trials added valuable insight and contributed to scientific discoveries worldwide in the ongoing fight to prevent and treat the virus.

“The COVID-19 pandemic issued a clear and present call to action for the global community to optimize and sustain clinical trials infrastructure capabilities,” said Kevin J. Tracey, MD, president and CEO of the Feinstein Institutes. “By leading COVID-19 clinical trials at Northwell Health, Dr. Brennan demonstrated what excellence in leadership can accomplish during a pandemic. She is a valuable asset to the ACRP.”

Dr. Brennan also serves on the oncology advisory board with the Society for Clinical Research Sites and is a member of the American College of Healthcare Executives. She has authored numerous textbook chapters, co-authored over 25 manuscripts and abstracts. Dr. Brennan is an adjunct professor at Yeshiva University, where she teaches a clinical trials and research management class for the Masters of Science, biotechnology and entrepreneurship program.

In 2021, Dr. Brennan was featured during the ACRP North Texas Chapter during a special event around COVID-19 long-haulers and a Novartis meeting to discuss diversity in clinical trials. In 2022, Dr. Brennan is slated to speak at the Critical Research as a Care Option conference.

For more information about the Feinstein Institutes’ clinical trials, click here.

About the Feinstein Institutes

The Feinstein Institutes for Medical Research is the home of the research institutes of Northwell Health, the largest health care provider and private employer in New York State. Encompassing 50 research labs, 3,000 clinical research studies and 5,000 researchers and staff, the Feinstein Institutes raises the standard of medical innovation through its five institutes of behavioral science, bioelectronic medicine, cancer, health system science, and molecular medicine. We make breakthroughs in genetics, oncology, brain research, mental health, autoimmunity, and are the global scientific leader in bioelectronic medicine – a new field of science that has the potential to revolutionize medicine. For more information about how we produce knowledge to cure disease, visit http://feinstein.northwell.edu and follow us on LinkedIn.

Contacts

Matthew Libassi
631-793-5325
mlibassi@northwell.edu

Feinstein Institutes for Medical Research


Release Versions

Contacts

Matthew Libassi
631-793-5325
mlibassi@northwell.edu

More News From Feinstein Institutes for Medical Research

Northwell Health’s Feinstein Institutes’ Dr. Kevin J. Tracey Elected to National Academy of Inventors’ 2025 Class of Fellows

MANHASSET, N.Y.--(BUSINESS WIRE)--Recognized for his discovery of the inflammatory reflex and the burgeoning field of bioelectronic medicine, Kevin J. Tracey, MD, president and CEO of The Feinstein Institutes for Medical Research, has been named a Fellow of the National Academy of Inventors (NAI) as part of its 2025 Class. This prestigious recognition is the highest professional distinction awarded solely to inventors. The honor acknowledges those who have demonstrated a spirit of innovation in...

Feinstein Institutes’ Research Pinpoints Core Cause of Vascular Cognitive Impairment, Unlocking New Therapeutic Avenues for Cognitive Decline

MANHASSET, N.Y.--(BUSINESS WIRE)--Scientists at Northwell Health’s Feinstein Institutes for Medical Research have uncovered a critical mechanism driving vascular cognitive impairment (VCI), the world’s second most common form of dementia after Alzheimer’s disease. Their findings, published this month in Alzheimer’s & Dementia, pinpoint the dysregulation of vasoactive neuropeptides, or key regulators of blood-vessel tone, as the root cause of microvascular dysfunction in VCI. This discovery...

Feinstein Institutes Awarded $4M Grant to Develop AI-Powered Speech Based ‘Vital Signs’ to Improve Psychosis Diagnosis and Treatment

MANHASSET, N.Y.--(BUSINESS WIRE)--Northwell Health’s Feinstein Institutes for Medical Research received $4 million from the National Institute of Mental Health (NIMH) to improve how severe mental health conditions are assessed and treated. By using an AI-powered advanced speech and language analysis, the research aims to develop personalized metrics to gauge the severity of psychosis. This research has the potential to transform the way patients with mental illness are diagnosed and treated, le...
Back to Newsroom